Cipla, a pharmaceutical company, launched a point-of-care testing device for various noncommunicable diseases and other medical conditions. Cipla’s Cippoint device, another addition to its diagnostics laboratory product offerings, offers a wide range of testing parameters such as cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers.
The device is approved by the European In-Vitro Diagnostic Device Directive, according to the company, ensuring reliable testing solutions. Cippoint, an immunofluorescence-based quantitative analyzer, can assist healthcare professionals in receiving test results in 3 to 15 minutes, allowing for faster clinical decision-making. Cippoint, which aims to provide an accurate point-of-care testing experience to smaller healthcare establishments, has an automated system and user-friendly interface that can be used even in rural areas, mobile vans, and remote areas with limited infrastructure, according to Cipla.
“We are actively working to deliver innovative solutions that enable prompt and effective diagnosis, thereby filling gaps in the diagnostic ecosystem,” said CEO of Cipla’s India Business. Cipla stated in its annual report that its three-year strategy from 2020 to 2023 aims to build solutions around the care continuum, from simple and early diagnostics to effective treatment and monitoring. In FY 2021-22, the company also launched a suite of covid-19-related diagnostic tests (antibodies and rapid antigen).